1h Free Analyst Time
The human insulin drugs market in Brazil is forecasted to grow by USD 181.76 mn during 2023-2028, accelerating at a CAGR of 6.5% during the forecast period. The report on the human insulin drugs market in Brazil provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.Speak directly to the analyst to clarify any post sales queries you may have.
The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by rising prevalence of diabetes in Brazil, demographic transition in Brazil, and increasing awareness of insulin therapy.
The human insulin drugs market in Brazil is segmented as below:
By Product
- Basal insulin analog
- NPH (Neutral Protamine Hagedorn)
By Application
- Type I diabetes
- Type II diabetes
By Distribution Channel
- Retail
- Hospitals
The report on the human insulin drugs market in Brazil covers the following areas:
- Human insulin drugs market in Brazil sizing
- Human insulin drugs market in Brazil forecast
- Human insulin drugs market in Brazil industry analysis
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.
The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.
Table of Contents
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by Product
7 Market Segmentation by Application
8 Market Segmentation by Distribution Channel
9 Customer Landscape
10 Drivers, Challenges, and Trends
11 Vendor Landscape
12 Vendor Analysis
13 Appendix
List of Exhibits
Executive Summary
The publisher recognizes the following companies as the key players in the human insulin drugs market in Brazil: Becton Dickinson and Co., Biocon Ltd., Biomm, Eli Lilly and Co., Empreendimentos Pague Menos SA, Gulf Pharmaceutical Industries, MannKind Corp., Medtronic Plc, Merck and Co. Inc., Novartis AG, Novo Nordisk AS, Sanofi SA, and Wockhardt Ltd..Commenting on the report, an analyst from the research team said: 'The latest trend gaining momentum in the market is advent of biosimilars for treatment of diabetes.'
According to the report, one of the major drivers for this market is the rising prevalence of diabetes in Brazil.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Becton Dickinson and Co.
- Biocon Ltd.
- Biomm
- Eli Lilly and Co.
- Empreendimentos Pague Menos SA
- Gulf Pharmaceutical Industries
- MannKind Corp.
- Medtronic Plc
- Merck and Co. Inc.
- Novartis AG
- Novo Nordisk AS
- Sanofi SA
- Wockhardt Ltd.
